Related Experiment Video
Updated: Jul 14, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Massive intraperitoneal stromal tumour: two-year follow-up
D del Castillo Déjardin1, E M Carbajo-Ferré, M Hernández González
1Sant Joan University Hospital, Reus, Tarragona, Spain. ddelcastillo@grupsagessa.com
Summary
This case study shows a patient with high-grade gastrointestinal stromal tumors (GISTs) achieving remission two years post-surgery and Imatinib mesylate treatment. This highlights the effectiveness of combined therapy for advanced GIST.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GISTs) are rare neoplasms.
- Surgical resection was the primary treatment for GISTs.
- Advanced GISTs now benefit from multimodal therapy including targeted agents.
Observation:
- A patient presented with a high-grade GIST.
- Multiple intraperitoneal tumors were identified via laparotomy.
- Tumor burden included large masses up to 22cm and widespread peritoneal dissemination.
Findings:
- Cytoreductive surgery was performed, excising larger masses.
- Residual tumor implants were treated with Imatinib mesylate.
- The patient achieved remission and remained disease-free for two years post-treatment.
Implications:
- Imatinib mesylate demonstrates significant efficacy in managing advanced GIST.
- Combined surgical and pharmacological approaches improve patient outcomes.
- This case supports Imatinib mesylate as a crucial component in GIST treatment protocols.
